Product information and disease descriptionProduct descriptionProduct informationPharmacology
Pharmacodynamics
12 evidence topics · 12 sources
Serum tryptase and plasma SCF in CSU: phase 1b, intravenous dosing every 4 or 8 weeks
“Phase 1b double‐blind placebo‐controlled trial (NCT04538794) in adults with moderate‐to‐severe (urticaria activity score over 7 days [UAS7] ≥ 16) antihistamine–refractory CSU treated with intravenous barzolvolimab for 12 weeks with a 12‐week follow‐up in four sequentially enrolled cohorts (randomized 4:1 barzolvolimab:placebo): 0.5 mg/kg, Q4W (n = 9); 1.5 mg/kg, Q4W (n = 8); 3 mg/kg, Q8W (n = 9); and 4.5 mg/kg, Q8W (n = 9).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Serum tryptase, a specific marker for MCs, was suppressed at all barzolvolimab doses, and reduction below assay detection levels was generally observed at doses ≥ 1.5 mg/kg (Figure 2B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Maximal tryptase suppression and clinical activity were reached at doses ≥ 1.5 mg/kg, which are consistent with target saturation.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Plasma SCF increases mirrored the tryptase suppression kinetics, and both correlated well with clinical activity (Figure 2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The lowest dose (0.5 mg/kg) showed transient improvements in clinical activity that correlated with partial tryptase suppression, SCF increases, and subsequent recovery prior to the following dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All KIT‐dependent functions, including tissue MCs, hematological parameters, and hair color changes, are expected to recover once KIT signaling resumes following drug clearance, as has been observed in prior studies with barzolvolimab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum tryptase depletion in the phase 2 CSU trial
Baseline serum tryptase in CSU compared with healthy participants, and response by baseline tryptase: phase 2 post hoc analysis
Tryptase recovery during the 24-week follow-up period of the phase 2 CSU trial
Serum tryptase and plasma SCF in healthy volunteers: single intravenous doses
“A single ascending dose (0.3, 1, 3, and 9 mg/kg), double‐blinded placebo‐controlled phase 1a human healthy volunteer study (n = 32) was conducted to evaluate the safety, pharmacokinetics, and pharmacodynamics of CDX‐0159.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A single dose of CDX‐0159 at 0.3, 1, 3, and 9 mg/kg, or placebo was intravenously administered to healthy subjects (Table 1).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Tryptase reduction was manifest in all subjects dosed with CDX‐0159 at 24 h after the infusion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At the lowest dose of 0.3 mg/kg, plasma tryptase was reduced by approximately 50%, including the subject with high baseline tryptase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“At higher doses, tryptase levels were reduced below the lower limit of assay quantitation (LLoQ) (1 ng/ml) in all CDX‐0159 treated subjects for at least 3 weeks at 1 mg/kg, 6–14 weeks at 3 mg/kg and over 18 weeks at 9 mg/kg (Figure 4B and Figure S10).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“No significant change in tryptase was observed in the placebo group.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“We observed dose‐proportional increases in SCF levels that mirrored the effects of CDX‐0159 on plasma tryptase.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Together with the effect of the antibody on tryptase levels, these data provide additional evidence of systemic KIT saturation with CDX‐0159 at doses of 1 mg/kg and above.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Serum tryptase in healthy volunteers: single subcutaneous doses
Cold urticaria and symptomatic dermographism: skin mast cell depletion, tryptase, and SCF after one 3 mg/kg intravenous dose
Chronic inducible urticaria: kinetics of skin mast cell depletion and repopulation to Week 36
“Patients with two forms of CIndU (SD; n = 10 and ColdU; n = 10) received a single 3 mg/kg intravenous dose of barzolvolimab.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“As early as 1 week following drug administration, MC numbers rapidly decreased, reaching approximately 90% reduction after 8 weeks and with similar kinetics as reductions in serum tryptase and clinical symptoms (Figure S3).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“MCs only recovered partially 36 weeks after dosing (31% for tryptase and 38% for CD117 from baseline), suggesting that MCs can repopulate skin, albeit very slowly.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In contrast to IHC data, MC transcripts completely recovered by Week 36 (Figure 2A) and the kinetics closely mirrored that of clinical symptoms and serum tryptase (Figure 2B–D).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Our data demonstrate that KIT‐dependent MC reduction is fully reversible and that mature and reactive MCs repopulate skin from MC progenitors within several weeks following their depletion.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Eosinophilic esophagitis: esophageal intraepithelial mast cell counts at Week 12, phase 2
Prurigo nodularis: serum tryptase with a 450 mg loading dose, phase 2
Prurigo nodularis: serum tryptase and plasma SCF after a single intravenous dose
Nonclinical toxicology in cynomolgus monkeys: bone marrow, red blood cell mass, and hair color
“To support human trials, a GLP‐compliant toxicology study was performed with CDX‐0159 in cynomolgus monkeys with dose levels of 1, 10, and 75 mg/kg administered every two weeks for 13 weeks.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“CDX‐0159 was well tolerated with no significant changes in body weight, coagulation, clinical chemistry, ophthalmology, electrocardiography, respiratory, or neurological function during the treatment and recovery period.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Observations attributed to CDX‐0159‐included minimal increases in the myeloid to erythroid ratio in bone marrow smears in the animals dosed at 10 and 75 mg/kg at the end of dosing (day 85), with evidence of recovery by day 141 despite continued drug exposure in the recovery period (Figure 2B).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In addition, recoverable minimal/mild decreases in red blood cell mass parameters were observed (Figure 2C).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Hair color changes were noted in some high‐dose‐treated animals, consistent with inhibition of KIT activity in follicular melanocytes.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote